Cell Death and Survival

P-Cadherin Promotes Ovarian Cancer Dissemination Through Tumor Cell Aggregation and Tumor–Peritoneum Interactions

Akihiro Usui, Song Yi Ko, Nicolas Barengo, and Honami Naora

Abstract

More than 60% of patients who are diagnosed with epithelial ovarian cancer (EOC) present with extensive peritoneal carcinomatosis. EOC cells typically disseminate by shedding into the peritoneal fluid in which they survive as multicellular aggregates and then implant onto peritoneal surfaces. However, the mechanism that facilitates aggregation and implantation of EOC cells is poorly understood. The cell adhesion molecule P-cadherin has been reported to be induced during early progression of EOC and to promote tumor cell migration. In this study, P-cadherin not only promoted migration of EOC cells, but also facilitated the assembly of floating EOC cells into multicellular aggregates and inhibited anoikis in vitro. Furthermore, inhibiting P-cadherin by short hairpin RNAs (shRNA) or a neutralizing antibody prevented EOC cells from attaching to peritoneal mesothelial cells in vitro. In mouse intraperitoneal xenograft models of EOC, inhibition of P-cadherin decreased the aggregation and survival of floating tumor cells in ascites and reduced the number of tumor implants on peritoneal surfaces. These findings indicate that P-cadherin promotes intraperitoneal dissemination of EOC by facilitating tumor cell aggregation and tumor–peritoneum interactions in addition to promoting tumor cell migration.

Implications: Inhibiting P-cadherin blocks multiple key steps of EOC progression and has therapeutic potential.

Mol Cancer Res; 12(4); 504–13. ©2014 AACR.

Introduction

The lethality of epithelial ovarian cancer (EOC) stems from its propensity for intraperitoneal dissemination. More than 60% of EOC patients present with advanced-stage disease that has disseminated throughout the peritoneal cavity (1). These patients are treated with limited success by surgery and conventional chemotherapy and have a 5-year survival rate of less than 30% (1). Unlike many other types of solid tumors, EOC rarely spreads via hematogenous routes. The most widely recognized pattern of EOC dissemination is intraperitoneal "seeding" in which tumor cells passively shed into, and are transported by, the circulating peritoneal fluid (2–4). EOC cells are frequently present in ascites either as floating multicellular aggregates or as single cells. It is thought that aggregation of floating EOC cells prevents anoikis and also facilitates the implantation of tumor cells on to peritoneal surfaces such as the cavity wall, bowel serosa, and the omentum (3–5). These surfaces are lined by a monolayer of mesothelial cells that acts as a protective barrier against tissue injury and infection (6). Growth of tumor implants on peritoneal surfaces often causes substantial pain and leads to bowel obstruction. Targeting cell surface molecules that promote both the aggregation of EOC cells and their implantation, therefore, represents an attractive therapeutic approach to improve outcomes.

It is widely recognized that most types of epithelial tumors initially progress by undergoing epithelial-to-mesenchymal transition (EMT), a process that loosens adhesion between epithelial cells and eases their attachment to the basement membrane (7, 8). A hallmark of EMT is “cadherin-switching,” in which expression of the cell adhesion molecule E-cadherin decreases and expression of N-cadherin concomitantly increases (7, 8). EOC cells are thought to undergo an EMT-like process during early stages of disease progression. Clustering of collagen-binding integrins induces matrix metalloproteinase-9 that cleaves the E-cadherin ectodomain, thereby loosening adhesion between EOC cells and enabling tumor cells to shed (9). E-cadherin levels are often downregulated in floating ascitic EOC cells as compared with matching primary solid tumors (10). However, the mechanisms that mediate adhesion between floating EOC cells are poorly understood. Two independent studies have found a striking induction in levels of P-cadherin during early stages...
of EOC progression (11, 12). Induction of P-cadherin has been reported to increase migratory potential of EOC cells (13). P-cadherin has also been found to be the most predominant type of cadherin expressed in malignant peritoneal effusions of patients with EOC and in normal peritoneal tissues (11, 14). These findings raise the possibility that P-cadherin might facilitate the assembly of floating EOC cells into multicellular aggregates and also mediate tumor–peritoneum interactions. In this study, we identified that inhibition of P-cadherin not only decreases EOC cell migration, but also decreases the aggregation of floating EOC cells, increases anoikis, and prevents EOC cells from implanting on to peritoneal surfaces. Targeting P-cadherin might, therefore, be a potential strategy to block multiple rate-limiting steps in the progression of EOC.

Materials and Methods

Antibodies and plasmids

Antibodies to human P-cadherin were purchased from BD Biosciences (for Western blot analysis) and Abcam (for neutralization). Antibody to mouse P-cadherin was purchased from Invitrogen. Other sources of antibodies were as follows: E-cadherin (Invitrogen), N-cadherin, Cdc42, Rac1, active caspase-3 (BD Biosciences), actin, and secondary antibodies (Sigma-Aldrich). pGIPZ lentiviral plasmids containing nontargeting short hairpin RNA (shRNA) and shRNAs targeting CDH3 (encoding P-cadherin) were purchased from Thermo Scientific. Myc-tagged dominant-negative mutant forms of Rac1 (T17N) and Cdc42 (T17N; ref. 15) were provided by Gary Bokoch (Scripps Research Institute, La Jolla, CA; Addgene plasmids 12984 and 12973).

Cell culture and transfection

SKOV3ip and OVCA429 cell lines were provided by Gordon Mills (MD Anderson Cancer Center, Houston, TX) and cultured in McCoy’s 5A medium and Minimum Essential Medium, respectively (Invitrogen). Cell lines were authenticated by the short tandem repeat analysis performed by the MD Anderson Cancer Center Characterized Cell Line Core Facility. The 293 cell line was purchased from American Type Culture Collection and cultured in Dulbecco’s Modified Eagle Medium (Invitrogen). All media were supplemented with 10% FBS and penicillin-streptomycin. Of note, 293 cells were transfected with pGIPZ plasmids by using lipofectamine 2000 reagent (Invitrogen). At 2 days thereafter, culture supernatants were harvested and used to infect SKOV3ip and OVCA429 cells. Infected tumor cell lines were selected with puromycin (0.5 μg/mL). Primary cultures of normal human omental mesothelial cells have been previously described (16) and were provided by Ernst Lengyel (University of Chicago, Chicago, IL).

Immunoprecipitation and Western blot analysis

Cell lysates were prepared by using M-PER buffer (Pierce Biotechnology), separated by SDS–PAGE and transferred to PVDF (polyvinylidene difluoride) membranes (GE Healthcare). Active forms of Rac1 and Cdc42 were detected in cell lysates by immunoprecipitation using GST (glutathione S-transferase)-tagged protein containing the PAK1 protein–binding domain (Cytoskeleton, Inc.)

Quantitative reverse transcription PCR

Transcripts of EMT-associated genes were analyzed by using SYBRGreen qPCR Master Mix (SABiosciences) and primers described in our previous work (17). RPL32 transcript levels were used as controls for normalization.

Cell migration assays

Tumor cells were seeded in the upper chamber in 24-well Transwell chambers (BD Biosciences) that were coated with Matrigel or left uncoated (5 × 10^4 cells/uncoated well; 1 × 10^5 cells/coated well). Migrating cells were assayed at 6 hours (for uncoated wells) and at 16 hours (for coated wells). Migrating cells were stained with Giemsa solution and counted in five random ×100 microscopic fields per well. Three independent experiments were performed for each assay.

Cell viability and cell death assays

Cell viability was measured by the MITT assay (Roche). Tumor cells were seeded in 96-well plates (1 × 10^4 cells/well) that were coated with poly(2-hydroxyethyl methacrylate) (polyHEMA; Sigma-Aldrich) to block cell attachment to substratum as previously described (18). Cell death was measured by assaying mono- and oligonucleosomes in cell lysates by using the Cell Death Detection ELISA Kit (Roche). Three independent experiments were performed for each assay. Tumor cells were also assayed for cell death by staining with 7-amino actinomycin D (7AAD; Sigma-Aldrich) and with antibody to active caspase-3. Cells were stained with Hoechst dye (Sigma-Aldrich) to visualize nuclei and viewed by immunofluorescence microscopy. Staining was also evaluated by flow cytometry (FACSCalibur; BD Biosciences).

In vitro cell attachment assays

GFP-expressing tumor cells (1.5 × 10^4/well) were seeded in 96-well plates containing confluent monolayers of omental mesothelial cells as previously described (18). Where indicated, mesothelial cell monolayers were preincubated with neutralizing P-cadherin antibody or with control IgG at a final concentration of 10 μg/mL before seeding of tumor cells. At 1 hour after seeding of tumor cells, wells were washed with PBS to remove unattached tumor cells. Attached tumor cells were viewed by immunofluorescence microscopy and counted in three random ×200 microscopic fields per well. Three independent experiments were performed for each assay.

Mouse intraperitoneal xenograft studies

Four-week-old female nude mice were purchased from the National Cancer Institute (Frederick, MD) and were inoculated intraperitoneally with 2 × 10^6 cells of GFP-expressing SKOV3ip lines (n = 5 mice/group). Mice were euthanized by CO_2 asphyxiation at 3 weeks thereafter. In other sets of experiments, SKOV3ip cells were preincubated for 1 hour with neutralizing antibody to human P-cadherin (50 μg), with control IgG or with no antibody, and then injected into...
mice. Mice were sacrificed at 3 days thereafter. Mice were also inoculated with SKOV3ip cells together with neutralizing antibody to mouse P-cadherin (50 μg), with control IgG or with no antibody, and sacrificed at 10 days thereafter. GFP-expressing tumor cells were visualized under a Leica MZML III stereomicroscope equipped with a mercury lamp power supply and GFP filter set. Intrahepatic tumor burden was quantified by measuring areas of fluorescence signals within the abdominal cavity in captured images by using Image Pro Plus 5.0 software (Media Cybernetics) as previously described (19). Cells were collected from peritoneal fluid and stained with Hoechst dye, 7AAD, and phycoerythrin-conjugated anti-active caspase-3 antibody. Cell clusters were gently disaggregated by passing through 35 μm nylon mesh. Immediately thereafter, 7AAD and active caspase-3 staining was analyzed by flow cytometry within the gated population of GFP+ tumor cells. Sections of formalin-fixed, paraffin-embedded solid tumor tissues were stained with hematoxylin–eosin (H&E). TUNEL (terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling)-staining of tissue sections was performed by using the in situ Cell Death Detection Kit (Roche). Evaluation of staining is described in Supplemental Fig. S4C.

Statistical analysis
Statistical analysis was performed by using STATISTICA6 software (StatSoft Inc.). Values of statistical significance of data were assessed by the unpaired two-tailed Student t test. Data, mean ± SD; P values of < 0.05 were considered significant.

Results
Knockdown of P-cadherin inhibits migration of EOC cells
We evaluated several shRNAs that targeted different regions of the CDH3 gene for their ability to specifically downregulate levels of P-cadherin, but not E- and N-cadherin levels, in the OVCA429 and SKOV3ip EOC cell lines (Fig. 1A). The two most effective shRNAs (sh3-PCAD and sh4-PCAD) were used for further study. As compared with control OVCA429 cells that expressed empty vector or nontargeting shRNA, OVCA429 cells in which P-cadherin was knocked down showed significantly reduced motility (P < 0.005; Fig. 1B). Identical results were obtained using SKOV3ip cells (Fig. 1B). Knockdown of P-cadherin also significantly reduced tumor cell invasiveness (P < 0.001; Fig. 1C). These observations are consistent with studies using other EOC cell lines and cell lines derived from pancreatic and bladder cancers in which overexpression of P-cadherin was found to increase cell motility and invasion (13, 20, 21). Because EMT is associated with alterations in cadherin expression (7, 8), we evaluated the possibility that knockdown of P-cadherin reduces cell migration by inhibiting EMT. Knockdown of P-cadherin did not alter the expression of genes encoding transcription factors that orchestrate EMT such as Snail, Slug, Zeb1, Zeb2, and Twist (Supplementary Fig. S1). It has been reported that P-cadherin promotes cell motility and invasion by activating the Rho GTPases Rac1 and Cdc42 (13, 20). Consistent with the observed decreases in EOC cell motility and invasion, levels of the active forms of Rac1 and Cdc42 were reduced when P-cadherin was knocked down (Supplementary Fig. S2A). Dominant-negative mutant forms of Rac1 and Cdc42 that block activation of these Rho GTPases (15) significantly inhibited tumor cell
motility and invasion ($P < 0.005$), and this inhibition was as effective as that observed when P-cadherin was knocked down (Supplementary Fig. S2B–S2D).

**P-cadherin promotes aggregation of floating EOC cells and inhibits anoikis**

It is widely thought that the assembly of floating EOC cells into multilayered structures enables these cells to escape anoikis (3, 4). To evaluate whether P-cadherin promotes aggregation of floating EOC cells, we incubated cells of control and sh-PCAD EOC lines as suspension cultures in plates coated with polyHEMA, an inert polymer that prevents cells from adhering to substratum. Whereas control cells formed large aggregates, suspension cultures of sh-PCAD cells comprised of small aggregates and single cells (Fig. 2A). Cell death was observed in sh-PCAD cells as detected by staining with 7AAD (Fig. 2B). In contrast, control cells were mostly viable (Fig. 2B). The increased levels of cell death in suspension cultures of sh-PCAD cells were confirmed by assaying mono- and oligonucleosomes in cell lysates (Fig. 2C). Identical results were obtained using OVCAR429 and SKOV3ip cells (Fig. 2C). Whereas knockdown of P-cadherin reduced cell viability in suspension cultures, knockdown of P-cadherin did not affect the viability of cells when cultured as adherent monolayers on uncoated plates (Fig. 2D). Together, these observations indicate that P-cadherin promotes the assembly of floating tumor cells into aggregates and inhibits anoikis.

To confirm our findings, we evaluated the effects of a P-cadherin neutralizing antibody on cell aggregation and anoikis. Suspension cultures of EOC cells that were treated with P-cadherin neutralizing antibody comprised of small aggregates and single cells, whereas cells that were treated with control IgG or with no antibody formed large aggregates (Supplementary Fig. S3A). As compared with control cells, cells that were treated with P-cadherin antibody exhibited significantly higher levels of cell death ($P < 0.01$; Supplementary Fig. S3B). Whereas P-cadherin antibody blocked cell aggregation, cell aggregation was not markedly affected by dominant-negative mutant forms of Rac1 and Cdc42 (Supplementary Fig. S3C). This suggests that the Rho GTPase pathway downstream of P-cadherin is alone insufficient to facilitate intercellular interactions. Inactivation of Rac1 and Cdc42 increased anoikis, but not as effectively as P-cadherin inhibition (Supplementary Fig. S3D).

**P-cadherin facilitates EOC–mesothelial cell interactions**

P-cadherin is the most predominant type of cadherin expressed in normal peritoneal tissues as well as in malignant peritoneal effusions (11, 14). We, therefore, investigated the possibility that P-cadherin facilitates interactions between EOC cells and mesothelial cells that line the peritoneal surfaces. To evaluate the effect of inhibiting P-cadherin in EOC cells, attachment assays were performed by seeding equivalent numbers of control and sh-PCAD EOC cells onto confluent monolayers of mesothelial cells isolated from normal human omentum. The numbers of sh-PCAD EOC cells that bound to mesothelial cells were significantly lower than the numbers of bound control EOC cells ($P < 0.01$; Fig. 3A and B). In reciprocal experiments, we evaluated the effect of inhibiting P-cadherin in mesothelial cells by preincubating mesothelial monolayers with neutralizing P-cadherin antibody before seeding EOC cells. Preincubation of mesothelial cells with P-cadherin antibody significantly reduced the number of bound EOC cells, as compared with mesothelial cells that were preincubated with control IgG or with no antibody ($P < 0.005$; Fig. 3C and D). Together, these findings indicate that P-cadherin facilitates interactions between EOC cells and peritoneal mesothelial cells.

**Blocking P-cadherin decreases viability of floating tumor cells and prevents tumor cell attachment in vivo**

To confirm the findings of our *in vitro* studies, we evaluated the effects of blocking P-cadherin in peritoneal attachment of EOC cells *in vivo*. On the basis of our prior experience using mouse intraperitoneal xenograft models derived from SKOV3ip cells (17), the earliest time point at which peritoneal tumor implants can be detected in mice is at 10 days following tumor cell inoculation. To evaluate the effect of blocking P-cadherin on peritoneal attachment of human EOC cells, mice were injected intraperitoneally with GFP-expressing SKOV3ip cells together with neutralizing antibody to mouse P-cadherin, control IgG or no antibody. Mice were sacrificed at 10 days thereafter. Tumor implants that were attached to the peritoneal cavity wall were viewed under a fluorescence stereoscope and counted (Fig. 4A). The numbers of tumor nodules in mice that were treated with P-cadherin antibody were significantly fewer than the numbers of tumor nodules in mice that treated with control IgG or with no antibody ($P < 0.02$; Fig. 4B). These findings indicate that P-cadherin facilitates interactions between peritoneal mesothelial cells and EOC cells.

We also evaluated the effect of blocking P-cadherin on the viability of floating EOC cells. Mice were inoculated intraperitoneally with GFP-expressing SKOV3ip cells that had been preincubated with neutralizing antibody to human P-cadherin, control IgG or no antibody, and were sacrificed at 3 days thereafter. Cell death was evaluated within the population of GFP+ tumor cells in the peritoneal fluid by flow cytometric analysis of 7AAD staining. As shown in Fig. 4C, the proportion of floating tumor cells that exhibited cell death was substantially higher in the P-cadherin antibody–treated model than in the control models. These observations are highly consistent with our findings in suspension cultures of SKOV3ip cells (Fig. 2B and C; Supplementary Fig. S3B), and support the notion that P-cadherin prevents anoikis in EOC cells.

**Knockdown of P-cadherin prevents EOC progression in intraperitoneal xenograft models**

In subsequent experiments, we evaluated the overall effects of inhibiting P-cadherin on EOC progression in intraperitoneal xenograft models. Mice were inoculated intraperitoneally with equivalent numbers of control and sh-PCAD SKOV3ip cells that expressed GFP and were sacrificed at 3 weeks thereafter. Mice that were inoculated with control SKOV3ip
cells developed numerous tumor implants, particularly on the mesentery and peritoneal cavity wall (Fig. 5A). In contrast, mice that were inoculated with sh-PCAD SKOV3ip cells developed fewer discrete peritoneal nodules (Fig. 5A). Consistent with these observations, the overall tumor burden in mice with sh-PCAD tumors as compared with the control group was significantly reduced ($P < 0.01$; Fig. 5B). The volume of ascites was also significantly reduced ($P < 0.02$; Fig. 5B). In addition, tumor implants derived from control SKOV3ip cells were locally invasive, whereas invasion of adjacent tissues was not observed for tumors derived from sh-PCAD SKOV3ip cells (Fig. 5C).

Figure 2. Knockdown of P-cadherin inhibits aggregation of floating EOC cells and increases anoikis. A to C, cells of control and sh-PCAD EOC lines were incubated as suspension cultures in polyHEMA-coated plates for 3 days. A, morphology of control and sh-PCAD SKOV3ip cells viewed under phase-contrast microscopy. Bar, 100 μm. B, SKOV3ip cells were stained with Hoechst dye to visualize nuclei and with 7AAD to detect cell death, and viewed under immunofluorescence microscopy. Bar, 50 μm. The percentage of 7AAD$^+$ cells was calculated from the number of 7AAD$^+$ cells and total number of cells within a $\times$100 microscopic field. Five random fields were scored per assay. The average total number of cells in one field was 80. C, cell death was measured by assaying mono- and oligonucleosomes in cell lysates by ELISA. D, cell lines were incubated as adherent monolayers on uncoated plates. Cell viability was measured daily by MTT assay. B to D, average results of three independent experiments.
Although the overall tumor burden was reduced in mice with sh-PCAD tumors, there was no significant difference in the mitotic activity of solid intraperitoneal tumors derived from control and sh-PCAD tumor cells (Supplementary Fig. S4A and S4B). These observations are consistent with the observed lack of effect of P-cadherin on EOC cell proliferation per se (Fig. 2D). There was also no significant difference in the level of cell death in solid intraperitoneal tumors derived from control and sh-PCAD tumor cells (Supplementary Fig. S4C and S4D). Floating tumor cells in ascites that were collected from the control models were present as large aggregates, whereas ascites collected from sh-PCAD models contained smaller aggregates or single floating tumor cells (Fig. 5D). Cell death was evaluated within the population of GFP⁺ ascitic tumor cells by flow cytometric analysis of 7AAD. As shown in Fig. 5E, the proportion of ascitic tumor cells that exhibited cell death was substantially higher in the sh-PCAD model than in the control model. This finding was confirmed by evaluating the level of active caspase-3 in ascitic tumor cells (Fig. 5F). Collectively, these findings indicate that inhibiting P-cadherin prevents EOC progression via the combinatorial effects of inhibiting aggregation and survival of ascitic tumor cells, peritoneal attachment, and invasiveness.

Discussion

Intraperitoneal “seeding” is a distinctive pattern of dissemination that is unique to EOC and markedly differs from the hematogenous or lymphatic metastasis found for many other types of tumors. A key and initial rate-limiting step in the “seeding” of EOC is the survival of floating tumor cells in the peritoneal fluid. It is widely recognized that aggregation enables floating tumor cells to escape anoikis, although it is unclear whether tumor cells shed into the peritoneal fluid as aggregates or shed as single cells that then assemble into aggregates (3). The mechanisms that mediate adhesion between floating EOC cells are poorly understood. EOC cells express several integrins and extracellular matrix (ECM) proteins, and interactions between α5β1 integrin and fibronectin have been reported to mediate assembly of EOC cells into spheroids (22). Cadherins are transmembrane glycoproteins that have well-established functions in mediating homophilic cell adhesion (7). The role of cadherins in regulating cell

![Figure 3](image-url)
aggregation and anoikis varies depending on the type of cell. For example, treatment of Ewing sarcoma cells with E-cadherin neutralizing antibody increases anoikis sensitivity (23), whereas knockdown of E-cadherin in mammary epithelial cells confers anoikis resistance (24). Inhibition of N-cadherin–mediated intercellular interactions increases apoptosis in melanoma cells (25). Studies of clinical specimens of EOC have implicated the importance of P-cadherin, rather than of E- and N-cadherins, in facilitating aggregation of floating EOC cells. P-cadherin has been found to be the predominant type of cadherin expressed in tumor cells in the peritoneal fluid of patients with EOC (11). On the other hand, expression levels of E-cadherin and N-cadherin have been found to be markedly reduced in floating tumor cells as compared with solid tumors (10, 11).

In this study, we provide evidence that P-cadherin facilitates the assembly of floating EOC cells into multicellular aggregates. Our studies support the notion that P-cadherin primarily inhibits anoikis by promoting tumor cell aggregation, but it is not possible to exclude the possibility that P-cadherin also promotes cell survival by a mechanism that is independent of cell aggregation. This possibility seems unlikely because inhibition of P-cadherin decreased the viability of tumor cells in suspension cultures but not when tumor cells were cultured as adherent monolayers. Furthermore, inhibition of P-cadherin increased cell death in ascitic tumor cells in xenograft models but did not increase cell death in solid tumors. Classical cadherins such as P-cadherin primarily promote homotypic interactions (i.e., between cadherins of the same type; ref. 7). Nevertheless, it is possible that P-cadherin might also promote aggregation of EOC cells by facilitating the clustering of other surface molecules. There is evidence in some cell types that EMT confers anoikis resistance (24). The possibility that P-cadherin promotes anoikis resistance by inducing EMT is unlikely because knockdown of P-cadherin in EOC cells did not affect expression of genes that orchestrate EMT. P-cadherin is known to activate Rac1 and Cdc42 (20). Consistent with prior reports that Rac1 and Cdc42 increase anoikis resistance (26, 27), we observed increased anoikis when Rac1 and Cdc42 were inhibited. However, inhibition of these Rho GTPases did not markedly disrupt tumor cell aggregation and was not as effective as P-cadherin inhibition in increasing anoikis. Although activation of Rac1 and Cdc42 could partially explain the ability of P-cadherin to confer anoikis resistance, our findings support the notion that P-cadherin primarily prevents anoikis by promoting tumor cell aggregation and indicate that downstream Rho GTPase signaling is alone insufficient to facilitate cell aggregation. This is not surprising as cell adhesion is achieved via interactions between the extracellular domains of two cadherin molecules of adjacent cells (7).

Because knockdown of P-cadherin did not decrease mitotic activity or cell death in solid intraperitoneal tumors, the reduction in overall intraperitoneal tumor burden in mice with sh-PCAD tumors as compared with control tumors is likely to be due to, or at least in part from, increased cell death in floating, ascitic tumor cells. This is supported by our short-term in vivo studies in which treatment with P-cadherin antibody increased cell death in floating tumor cells. Another important rate-limiting step in the progression of EOC is the implantation of floating tumor cells on to peritoneal surfaces. Our in vitro studies and short-term in vivo studies demonstrate that P-cadherin also facilitates interactions between EOC cells and peritoneal mesothelial cells. The observed reduction in overall intraperitoneal tumor burden in mice with sh-PCAD tumors could,
therefore, also be attributable to the decreased implantation capability of sh-PCAD tumor cells. Our findings support those of a recent study in which P-cadherin induction was implicated as the mechanism by which gonadotropin-releasing hormone receptor signaling stimulates attachment of EOC cells to mesothelial cells (28). The glycoprotein

---

**Figure 5.** Knockdown of P-cadherin prevents EOC progression in intraperitoneal (i.p.) xenograft models. Female nude mice were inoculated i.p. with equivalent numbers of GFP-expressing control and sh-PCAD SKOV3ip cells and were sacrificed at 3 weeks thereafter (n = 5 mice/group). A, tumor implants were viewed under a fluorescence stereoscope. B, i.p. tumor burden was quantified by measuring areas of fluorescence signals in captured images and is expressed as the average percentage of area of fluorescence within the abdominal cavity. Fluorescence signals on the peritoneal cavity wall were excluded from analysis. Also shown are volumes of ascites in mice. C, representative examples of H&E-stained tumor implants on the peritoneal cavity wall and diaphragm. Also shown are omental implants and the adjacent pancreas. Bar, 100 μm. D, cells were collected from ascites, stained with Hoechst dye to visualize nuclei (blue) and viewed under immunofluorescence microscopy. GFP-expressing ascitic tumor cells were visualized using a fluorescein filter. Bar, 50 μm. E and F, evaluation of cell death within the gated population of GFP+ tumor cells in ascites by flow cytometric analysis of (E) 7AAD staining and (F) staining of active caspase-3.

---

www.aacrjournals.org Mol Cancer Res; 12(4) April 2014

Published OnlineFirst January 21, 2014; DOI: 10.1158/1541-7786.MCR-13-0489

---

P-Cadherin Promotes Ovarian Cancer Dissemination

---

www.aacrjournals.org Mol Cancer Res; 12(4) April 2014

Downloaded from mcr.aacrjournals.org on June 19, 2017. © 2014 American Association for Cancer Research.
CA125, the most characterized EOC biomarker, has been also implicated in facilitating implantation by its ability to bind mesothelin, a glycoprotein that is expressed by mesothelial cells (29). The glycoprotein CD44 is widely expressed in ovarian cancers and binds hyaluronic acid, a glycosaminoglycan that is synthesized by mesothelial cells (30). Neutralizing antibodies to CD44 have been found to prevent EOC cells from attaching to mesothelial cells in vitro and to reduce the number of tumor implants in xenograft models (30–32). As observed for P-cadherin inhibition in our xenograft models, Strobel and colleagues found that treatment of mice with CD44 antibody did not inhibit tumor cell growth per se (31). Although EOC–mesothelial cell interactions can be inhibited by antibodies to CD44 and to β1 integrin, this inhibition has been found to be only partial (30, 32, 33). We likewise observed that inhibition of P-cadherin did not completely block attachment of EOC cells to mesothelial monolayers in vitro or totally eliminate implantation in vivo. Because increasing evidence indicates that EOC–peritoneum interactions are facilitated by multiple cell surface proteins, targeting a single adhesion molecule might not to be therapeutically efficacious.

Although several studies have demonstrated that various integrin heterodimers mediate attachment of EOC cells to mesothelial cells, other studies indicate that integrins primarily facilitate tumor cell interactions with the submesothelial ECM (18, 32–36). Electron microscopy studies by Niedbala and colleagues have suggested that mesothelial cells retract after coming in contact with tumor cells (37). Live cell imaging studies by Iwanicki and colleagues have revealed that spheroids of ovarian cancer cells physically displace mesothelial cells to gain access to the underlying stroma (33). These authors identified that spheroids use myosin-generated mechanical force to clear mesothelial cells at the site of contact in a manner that is dependent on α5β1 integrin and talin I (33). The role of P-cadherin in cell migration varies depending on the cell type. P-cadherin has been reported to inhibit migration of melanoma and oral squamous cell carcinoma cells (38, 39), but promotes migration of pancreatic and bladder cancer cells (20, 21). Our findings that knockdown of P-cadherin inhibits migration of OVCA429 and SKOV3ip3 cells are consistent with findings by Cheung and colleagues that overexpressing P-cadherin in the EOC cell line Caov-3 promotes cell migration (13). The notion that P-cadherin increases migration of EOC cells and also facilitates adhesion between floating EOC cells seems somewhat discordant. The ability of P-cadherin to promote both of these processes might stem from different mechanisms. Our observations that Rho GTPase inactivation and P-cadherin inhibition were almost equally effective in blocking EOC cell migration support prior reports that P-cadherin–mediated cell migration depends on Rho GTPase activation (20). In contrast, our findings indicate that Rho GTPase signaling alone is insufficient to facilitate cell adhesion. Furthermore, the ability of P-cadherin to promote aggregation of floating EOC cells and also invasiveness could explain the reported invasiveness of ascitic EOC spheroids (40). Indeed, EOC cells in ascites have been reported to be 4-fold more invasive than their solid tumor counterparts (10).

In summary, our study demonstrates that inhibiting P-cadherin blocks multiple and key steps of EOC progression. Together with prior reports that α5β1 integrin facilitates both the assembly of EOC cells into spheroids and breach of the mesothelial barrier (22, 33), our findings support a model in which implantation of EOC cells is dynamically and mechanistically coupled to the aggregation of floating EOC cells. A human monoclonal antibody to P-cadherin has been reported to inhibit metastasis in xenograft models of breast, colon, and prostate cancer and is undergoing evaluation in clinical trials (41). Our findings that blocking P-cadherin inhibits the viability and peritoneal attachment of floating EOC cells suggest that P-cadherin targeted therapy might not be highly beneficial for patients who have already developed carcinomatosis. On the other hand, anti–P-cadherin therapy might be effective in preventing formation of new implants after tumor-debulking surgery. However, because our study indicates that inhibiting P-cadherin alone does not inhibit tumor cell growth per se, combining anti–P-cadherin therapy with other cytotoxic agents warrants further investigation.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: A. Usui, S.Y. Ko, H. Naora
Development of methodology: A. Usui, S.Y. Ko, H. Naora
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Usui, S.Y. Ko, N. Barengo
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Usui, S.Y. Ko, H. Naora
Writing, review, and/or revision of the manuscript: A. Usui, S.Y. Ko, H. Naora
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): N. Barengo
Study supervision: H. Naora

Acknowledgments
The authors thank members of the Naora laboratory for helpful discussions.

Grant Support
This work was supported by Cancer and Prevention Research Institute of Texas (Austin, TX) grant RP120390 (to H. Naora) and U.S. NIH (Bethesda, MD) grant CA141078 (to H. Naora).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 12, 2013; revised December 5, 2013; accepted December 20, 2013; published OnlineFirst January 21, 2014.

References
P-Cadherin Promotes Ovarian Cancer Dissemination


www.aacrjournals.org  Mol Cancer Res; 12(4) April 2014 513

Downloaded from mcr.aacrjournals.org on June 19, 2017. © 2014 American Association for Cancer Research.
P-Cadherin Promotes Ovarian Cancer Dissemination Through Tumor Cell Aggregation and Tumor–Peritoneum Interactions

Akihiro Usui, Song Yi Ko, Nicolas Barengo, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-13-0489

Supplementary Material
Access the most recent supplemental material at: http://mcr.aacrjournals.org/content/suppl/2014/01/20/1541-7786.MCR-13-0489.DC1

Cited articles
This article cites 41 articles, 17 of which you can access for free at: http://mcr.aacrjournals.org/content/12/4/504.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at: /content/12/4/504.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.